Pfizer boasts over 30% increase in Q3 revenues against previous year
Amidst a share value slump and executive turmoil, Pfizer reported a robust quarter thanks in part to Covid-19 drug sales.
Amidst a share value slump and executive turmoil, Pfizer reported a robust quarter thanks in part to Covid-19 drug sales.
What's Your Reaction?
